Showing posts with label Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients. Show all posts
Showing posts with label Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients. Show all posts
Friday, December 1, 2017

FDA Approves Prevymis (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients

›
Merck & Co., Inc. ,  announced that the U.S. Food and Drug Administration (FDA) has approved Prevymis ( letermovir ) once-daily tab...